Free Newsletter
Children's drug consumers sue J&J for fraud
Consumers are accusing Johnson & Johnson (NYSE: JNJ) of fraud and racketeering in a lawsuit stemming from its recent children's drug recall. The buyers of those recalled meds are demanding cash refunds--rather than coupons for replacement products--in five suits seeking class-action status in federal court in Chicago.
The complaints say that the company's coupon offer is "worthless" because J&J's McNeil Consumer Healthcare has stopped making the products (if only temporarily), and parents might not want to use J&J children's drugs when they do come back on the market.
The suits also manage to rope in that "phantom recall" of Motrin tablets. The consumers' suits allege that quietly retrieving the Motrin packets was a "cover up" by a "criminal enterprise," Bloomberg reports, justifying punitive damages for racketeering.
The company is due to file a manufacturing-overhaul plan to FDA this week.
- see the Bloomberg coverage
- get more from Reuters
- read another story from Reuters
- check out the Wall Street Journal news
Related Articles:
J&J suffers 65% drop in pain-reliever sales
J&J unit recalls more OTC products
Bloomberg: McNeil president ordered 'phantom recall'
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: